Cycle Pharmaceuticals has launched Cycle Vita, a support platform for rare disease patients. The platform provides a vast range of high-quality support programs to both healthcare providers and rare disease patients across the United States, who have been prescribed a Cycle treatment.
“Cycle Vita is the ultimate expression of the heart of Cycle. At Cycle, we know that a patient’s wellbeing not only depends on life-changing therapy, but the care and support they receive throughout their treatment journey. That is why the Cycle Vita support platform provides individualized programs, led by a qualified, dedicated team of experts, to meet the needs of the underserved rare disease community.” says Antonio Benedetti, CEO, Cycle.
Cycle Vita will provide appropriate clinical, financial and emotional support to rare disease patients, as well as product information and support for healthcare professionals with relevant processes to access treatment efficiently.
“Cycle Vita has been developed with the idea of individualized patient care at its core. That’s why our nurse product support will be available 24/7, ready to provide appropriate personalized support to patients when they need it. Our team of Access specialists understand how difficult and time consuming it can be to navigate through all the paperwork and processes to access treatment for patients and can help appropriately streamline these processes from enrollment to prescription, and beyond,” says John Reid, Director of Patient Hub services.
Cycle Vita begins its journey launching support programs for Sajazir (icatibant) injection for patients with HAE providing 24/7 nurse product support, as well as Co-Pay, Bridge, and Quick start financial program support for eligible commercially insured patients.